Mental or Behavioral Dysfunction

LB Pharmaceuticals Files for $228M IPO to Fund Phase III Schizophrenia Drug

2 days ago talkbio0Tagged Alzheimer 's psychosis, amisulpride, Clinical Nurse Specialists, Depression, Bipolar, IPO, LB-102, Nasdaq, Phase 3 Clinical Trials, Pounds, Schizophrenia, United States Food and Drug Administration

LB Pharmaceuticals; IPO; Phase III trial; schizophrenia; LB-102; biotech; CNS therapeutics; bipolar depression; Alzheimer’s psychosis; amisulpride; FDA; Nasdaq

Hundreds of HHS Workers Accuse RFK Jr. of Destroying Public Health Trust After CDC Attack

2 weeks ago talkbio0Tagged CDC, Centers for Disease Control and Prevention (U.S.), federal workers, harassment, Health, HHS, Misinformation, Public Health Trust, RFK Jr., vaccine skepticism, Violence

RFK Jr.; Health and Human Services (HHS); CDC attack; public health trust; misinformation; vaccine skepticism; harassment; violence against federal workers

Reunion Psychedelic Therapy Advances to Pivotal Trials after Postpartum Depression Success

3 weeks ago talkbio0Tagged Clinical Trials, Depression, Postpartum, Montgomery-Åsberg Depression Rating Scale, Montgomery-Asberg Depression Rating Scale Questionnaire, Neuroscience discipline, Phase 2 Clinical Trials, Phase 3 Clinical Trials, psychedelic therapy, RE104, RECONNECT, remission rates, Reunion

Reunion Neuroscience; RE104; psychedelic therapy; postpartum depression (PPD); Phase II trial; Phase III trial; RECONNECT trial; clinical trial results; Montgomery-Åsberg Depression Rating Scale (MADRS); remission rates

CDC Launches ‘Free Mind’ Campaign Targeting Teen Substance Use and Mental Health

1 month ago talkbio0Tagged Adolescence, Alcohol or Other Drugs use, Centers for Disease Control and Prevention (U.S.), Drug Overdose, fentanyl, Free Mind ' Campaign, mental health, Strategy, teen suicide

CDC; Free Mind campaign; youth mental health; substance use; drug overdose; fentanyl; teen suicide; coping strategies

Atai’s Schizophrenia Drug Fails to Improve Cognition in Phase 2 Study

1 month ago talkbio0Tagged Atai Life Sciences, CIAS, clinical endpoints, Clinical trial failure, Cognition, Impaired cognition, inidascamine, Recognify Life Sciences, Schizophrenia

Atai Life Sciences; Recognify Life Sciences; inidascamine; schizophrenia; cognitive impairment; Phase 2b trial; clinical trial failure; cognition; CIAS; clinical endpoints

FDA Advisory Committee Rejects Lundbeck and Otsuka’s PTSD Bid for Rexulti

2 months ago talkbio0Tagged Advisory Committees, brexpiprazole, Clinical Trials, drug efficacy, Lundbeck, Otsuka, Post-Traumatic Stress Disorder, Rexulti, sertraline, United States Food and Drug Administration

Lundbeck; Otsuka; Rexulti; FDA advisory committee; PTSD; brexpiprazole; sertraline; clinical trials; drug efficacy; setback

Trump’s CDC Nominee Susan Monarez Affirms Vaccine Safety and Access Commitment

3 months ago talkbio0Tagged alliance, Autistic Disorder, Centers for Disease Control and Prevention (U.S.), Confirmation, Gavi Vaccine, Monarez, Nominee, Robert F. Kennedy Jr., Senate, Susan, Trump administration, Vaccine Safety, Vaccines

Susan Monarez; CDC nominee; vaccines; Trump administration; vaccine safety; autism; Senate confirmation; Robert F. Kennedy Jr.; Gavi Vaccine Alliance

Compass Pathways Achieves Phase 3 Win for Psilocybin in Depression, Yet Stock Tumbles

3 months ago talkbio0Tagged Clinical Trials, COMP360, Compass Pathways, Investor Reaction, Mental Depression, Psilocybin, Stock Decline, treatment-resistant depression, United States Food and Drug Administration

Compass Pathways; COMP360; psilocybin; Phase 3 trial; depression; treatment-resistant depression; clinical trial; stock decline; investor reaction; FDA

Draig Therapeutics Raises $140M Series A to Advance Neuropsychiatric Drug Pipeline

3 months ago talkbio0Tagged AMPA receptor modulator, Cardiff University, Draig, DT-101, GABA Modulators, Mental Depression, neuropsychiatric drugs, SV Health Investors

Draig Therapeutics; $140M Series A; neuropsychiatric drugs; DT-101; depression treatment; AMPA receptor modulator; GABA modulators; biotech funding; Cardiff University; SV Health Investors

Sage Therapeutics Acquired by Supernus Pharmaceuticals in $561M Deal

3 months ago talkbio0Tagged Acquisition, Biogen, Deal Value, Depression, Postpartum, Drug Industry, Supernus Pharmaceuticals, Zurzuvae

Sage Therapeutics; Supernus Pharmaceuticals; acquisition; Zurzuvae; postpartum depression; biotech; pharmaceutical industry; major depressive disorder; Biogen; deal value